Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heimberger, A. B.
Right arrow Articles by Sampson, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heimberger, A. B.
Right arrow Articles by Sampson, J. H.
Clinical Cancer Research Vol. 8, 3496-3502, November 2002
© 2002 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Brain Tumors in Mice Are Susceptible to Blockade of Epidermal Growth Factor Receptor (EGFR) with the Oral, Specific, EGFR-Tyrosine Kinase Inhibitor ZD1839 (Iressa)1

Amy B. Heimberger2, Chris A. Learn2, Gary E. Archer, Roger E. McLendon, Tracy A. Chewning, Frank L. Tuck, John B. Pracyk, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner and John H. Sampson3

Departments of Surgery (Neurosurgery) [A. B. H., C. A. L., G. E. A., T. A. C., F. L. T., J. B. P., A. H. F., H. S. F., J. H. S.] and Pathology [R. E. M., H. S. F., D. D. B.], Duke University Medical Center, Durham, North Carolina 27710

Iressa (ZD1839) is a p.o.-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that blocks signal transduction pathways implicated in cancer cell proliferation, survival, and host-dependent processes promoting cancer growth. EGFR is up-regulated in primary malignant tumors of the central nervous system (CNS) and in many systemic tumors that metastasize to the CNS. The purpose of our study was to evaluate the efficacy and toxicity of p.o.-administered ZD1839 for the treatment of established intracerebral (i.c.) tumors expressing EGFR or the tumorigenic mutated variant EGFRvIII, which is constitutively phosphorylated. Oral administration of ZD1839 at 50 or 100 mg/kg/day for 3 weeks in athymic mice with established i.c. A431 human epidermoid carcinoma expressing EGFR increased median survival by 88% (P = 0.009) and 105% (P < 0.001), respectively. Additionally, there was no evidence of systemic or CNS toxicity. However, ZD1839 failed to inhibit either s.c. or i.c. in vivo tumor growth when tumorigenicity was conferred by EGFRvIII. Western blotting revealed that treatment with ZD1839 virtually ablated phosphorylation of EGFR Tyr-1173 in A431 tumors. However, treatment of NR6M tumors with ZD1839 only partially decreased phosphorylation of EGFRvIII Tyr-1173 while up-regulating overall expression, suggesting that EGFRvIII may not be susceptible to the same molecular mechanisms of tyrosine kinase inhibition as EGFR. In conclusion, ZD1839 is active in a brain tumor model expressing EGFR, but not EGFRvIII, as EGFR mutations may lead to relative therapeutic resistance. On the basis of these observations, we believe that clinical trials of ZD1839 against brain tumors expressing EGFR are warranted, but that special consideration should be given to tumors that coexpress EGFRvIII.




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
J. W. Polli, J. E. Humphreys, K. A. Harmon, S. Castellino, M. J. O'Mara, K. L. Olson, L. St. John-Williams, K. M. Koch, and C. J. Serabjit-Singh
The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions
Drug Metab. Dispos., April 1, 2008; 36(4): 695 - 701.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Pattarozzi, M. Gatti, F. Barbieri, R. Wurth, C. Porcile, G. Lunardi, A. Ratto, R. Favoni, A. Bajetto, A. Ferrari, et al.
17 -Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment
Mol. Pharmacol., January 1, 2008; 73(1): 191 - 202.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cappuzzo, C. Ligorio, P. A. Janne, L. Toschi, E. Rossi, R. Trisolini, D. Paioli, A. J. Holmes, E. Magrini, G. Finocchiaro, et al.
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial
J. Clin. Oncol., June 1, 2007; 25(16): 2248 - 2255.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. G. Johns, R. M. Perera, S. C. Vernes, A. A. Vitali, D. X. Cao, W. K. Cavenee, A. M. Scott, and F. B. Furnari
The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization
Clin. Cancer Res., March 15, 2007; 13(6): 1911 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Tanos and A. M. Pendergast
Abl Tyrosine Kinase Regulates Endocytosis of the Epidermal Growth Factor Receptor
J. Biol. Chem., October 27, 2006; 281(43): 32714 - 32723.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Dragovich, S. McCoy, C. M. Fenoglio-Preiser, J. Wang, J. K. Benedetti, A. F. Baker, C. B. Hackett, S. G. Urba, K. S. Zaner, C. D. Blanke, et al.
Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127
J. Clin. Oncol., October 20, 2006; 24(30): 4922 - 4927.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi, J. L. Hunt, M. L. Freilino, M. W. Graner, C. J. Wikstrand, D. D. Bigner, et al.
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
Clin. Cancer Res., September 1, 2006; 12(17): 5064 - 5073.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. A. Edwards, M. Verreault, B. Thiessen, W. H. Dragowska, Y. Hu, J. H.F. Yeung, S. Dedhar, and M. B. Bally
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.
Mol. Cancer Ther., March 1, 2006; 5(3): 645 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Rich, S. Sathornsumetee, S. T. Keir, M. W. Kieran, A. Laforme, A. Kaipainen, R. E. McLendon, M. W. Graner, B.K. A. Rasheed, L. Wang, et al.
ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors
Clin. Cancer Res., November 15, 2005; 11(22): 8145 - 8157.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. D. Britten
Targeting ErbB receptor signaling: A pan-ErbB approach to cancer
Mol. Cancer Ther., October 1, 2004; 3(10): 1335 - 1342.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. L. Ceresoli, F. Cappuzzo, V. Gregorc, S. Bartolini, L. Crino, and E. Villa
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
Ann. Onc., July 1, 2004; 15(7): 1042 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y.-P. Lim, C. Y. Wong, L. L. Ooi, B. J. Druker, and R. J. Epstein
Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers: Implications for Adjuvant Use of Kinase-Inhibitory Drugs
Clin. Cancer Res., June 15, 2004; 10(12): 3980 - 3987.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Zhang, Y.-f. Zhang, J. Bryant, A. Charles, R. J. Boado, and W. M. Pardridge
Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer
Clin. Cancer Res., June 1, 2004; 10(11): 3667 - 3677.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Haringhuizen, H. van Tinteren, H. F. R. Vaessen, P. Baas, and N. van Zandwijk
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients
Ann. Onc., May 1, 2004; 15(5): 786 - 792.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Learn, T. L. Hartzell, C. J. Wikstrand, G. E. Archer, J. N. Rich, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson
Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme
Clin. Cancer Res., May 1, 2004; 10(9): 3216 - 3224.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. G. Johns, R. B. Luwor, C. Murone, F. Walker, J. Weinstock, A. A. Vitali, R. M. Perera, A. A. Jungbluth, E. Stockert, L. J. Old, et al.
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478
PNAS, December 23, 2003; 100(26): 15871 - 15876.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Li, C.-M. Chang, M. Yuan, W. G. McKenna, and H.-K. G. Shu
Resistance to Small Molecule Inhibitors of Epidermal Growth Factor Receptor in Malignant Gliomas
Cancer Res., November 1, 2003; 63(21): 7443 - 7450.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.